abr
gener
accompani
viral
upper
respiratori
tract
infect
multipl
factor
predispos
person
bacteri
infect
damag
normal
mucociliari
clearanc
allergyinflammatori
diseas
environment
factor
dental
infect
anatom
variat
among
other
wide
recogn
bacteria
abr
pneumonia
h
influenza
catarrhali
aureu
speci
anaerob
bacteria
may
also
contribut
infect
interestingli
payn
colleagu
perform
metaanalyt
studi
report
microbiolog
abr
evalu
common
bacteri
occurr
within
sinu
report
show
maxillari
sinu
contain
h
influenza
pneumonia
catarrhali
aureu
respect
hand
bacteria
found
respect
middl
meatu
furthermor
brook
gober
show
pneumonia
decreas
h
influenza
pyrogen
aureu
increas
respect
chang
catarrhali
find
determin
nasopharyng
cultur
taken
children
administr
pneumococc
conjug
vaccin
aureu
commonli
associ
pathogenesi
sphenoid
sinus
pneumococc
vaccin
present
unit
state
aid
reduct
recoveri
rate
pneumonia
increas
rate
h
influenza
addit
recoveri
rate
pneumonia
antibioticresist
strain
found
divers
vaccin
gramneg
bacteria
includ
p
aeruginosa
determin
associ
nosocomi
origin
acut
sinus
immunocompromis
patient
cystic
fibrosi
approxim
acut
sinus
patient
shown
least
one
pathogen
bacteria
speci
within
sinu
aspir
other
multipl
bacteri
speci
bacteria
associ
acut
sinus
colon
normal
nasal
flora
interestingli
becom
pathogen
accumul
sinu
although
environ
suffici
avail
grow
pyogen
aureu
anaerob
common
abr
found
less
abr
patient
sinus
result
dental
infect
chronic
manifest
except
studi
perform
respiratori
tractparanas
sinus
isol
show
pneumonia
margin
resist
penicillin
fulli
resist
interest
note
paranas
sinus
highest
rate
resist
bacteria
isol
region
also
resist
trimethoprimsulfamethoxazol
clindamycin
macrolid
doxycyclin
common
bacteria
intermedi
penicillin
resist
h
influenza
may
encapsul
unencapsul
type
b
form
margin
contributor
mening
incorpor
vaccin
unencapsul
strain
contribut
abr
adult
one
biggest
contributor
antimicrobi
resist
betalactamas
product
organ
interestingli
isol
paranas
sinu
determin
h
influenza
betalactamas
posit
catarrhali
bacteria
respons
abr
adult
case
betalactamas
also
contribut
antibiot
resist
catarrhali
isol
paranas
sinu
betalactamas
posit
date
aureu
account
abr
episod
becom
common
pathogen
abr
mrsa
methicillinresist
aureu
still
contribut
rhinosinus
episod
grow
develop
aureu
drugresist
may
chang
treatment
strategi
futur
gramneg
organ
p
aeruginosa
e
coli
p
mirabili
k
pneumonia
enterobact
speci
notic
nosocomi
sinus
account
known
case
gramposit
organ
fungi
make
pathogen
respons
nosocomi
infect
polymicrobi
invas
observ
isol
crswnp
crssnp
compos
mani
form
common
condit
medicin
virus
sourc
cr
integr
host
dna
caus
infect
mucosa
upper
lung
previou
report
demonstr
rhinoviru
found
epitheli
cell
specimen
cr
patient
compar
none
control
cell
convers
anoth
studi
fail
confirm
find
show
virus
found
either
group
altogeth
data
indic
role
viru
infect
chronic
inflamm
cr
known
mechan
trigger
virusfirst
event
predispos
improv
cr
also
lack
interestingli
viral
infect
earli
age
connect
asthma
though
idea
proven
cr
believ
virusinduc
epigenet
chang
may
occur
host
life
develop
date
microbiota
analysi
nasal
sinu
cr
patient
perform
use
standard
lab
techniqu
epidermidi
level
found
higher
control
compar
cr
upon
comparison
ar
cr
greater
increas
level
gramneg
rod
aureu
anaerob
cr
moreov
research
determin
differ
bacteriolog
cr
nasal
normal
nasal
swab
similar
microbiolog
flora
observ
infect
noninfect
side
case
unilater
cr
addit
result
cultur
similar
upon
success
sinu
surgeri
report
confirm
bacteri
role
cr
pathogenesi
although
differ
like
due
discrep
procedur
associ
allerg
rhiniti
prior
antibiot
administr
sourc
materi
sinu
nasal
interestingli
research
neglect
role
epidermidi
occurr
organ
within
epitheli
cell
biofilm
possibl
produc
differ
bacteri
identif
rate
tradit
method
bacteria
cr
vari
comparison
ar
bacteria
record
mani
sampl
acquir
endoscopi
sinu
punctur
cr
patient
staphylococcu
aureu
mssa
mrsa
staphylococci
coagulaseneg
scn
h
influenza
catarrhali
pneumonia
intermediu
p
aeruginosa
n
speci
anaerob
bacteria
exact
role
microb
etiolog
cr
ambigu
contrast
ar
numer
research
divid
microbi
etiolog
cr
biggest
differ
may
lie
method
techniqu
use
multipl
report
shown
method
anaerob
recoveri
key
yield
sampl
specimen
analyz
studi
variabl
microbi
growth
may
also
caus
exposur
variou
broadspectrum
antibiot
patient
jyonouchi
colleagu
effect
induc
cr
rabbit
intrasinu
inocul
b
fragili
interestingli
identifi
immunoglobulin
g
igg
antibodi
b
fragili
organ
consist
previou
report
identifi
igg
antibodi
anaerob
organ
patient
cr
microbiolog
report
cr
regularli
establish
infect
polymicrobi
case
baselin
cr
suddenli
worsen
induc
new
symptom
acut
exacerb
cr
found
polymicrobi
mani
case
anaerob
bacteria
prevail
nevertheless
aerob
bacteria
typic
connect
ar
may
appear
gramneg
facult
aerob
bacteria
readili
determin
cr
patient
underw
endoscop
sinu
surgeri
aureu
commonli
found
bacteria
cr
patient
western
civil
interestingli
occurr
shown
much
lower
asian
crswnp
microbi
abund
command
elimin
role
pathogenesi
host
proof
bacteriaspecif
effect
exist
aureu
suggest
role
pathogenesi
least
subgroup
crswnp
patient
substanti
evid
concern
organ
crswnp
accru
last
ten
year
brought
staphylococc
superantigen
hypothesi
state
aureu
secret
superantigen
toxin
sag
augment
local
inflamm
polyp
antibiot
resist
worldwid
medic
issu
despit
benefici
technolog
advanc
improv
new
antimicrobi
agent
current
moder
approxim
develop
countri
accept
strategi
cut
prevent
antibiot
resist
complic
approach
improv
public
health
sinc
import
reason
bacteri
resist
misus
agent
strategi
address
ration
prescript
antibiot
plan
nationwid
antibiot
restrict
program
effici
decreas
antibioticresist
rate
coagulaseneg
staphylococcu
aureu
frequent
found
gramposit
aerob
patient
cr
h
influenza
p
aeruginosa
frequent
found
gramneg
aerob
though
precis
role
pathogen
pathophysiolog
remain
explain
often
cultur
cr
patient
may
import
diseas
modifi
mainli
foundat
precis
microbiolog
cr
deriv
endoscop
cultur
necessari
bring
accur
antimicrobi
therapi
particularli
import
given
antibiot
resist
concern
uncontrol
patient
growth
antibiot
resist
ar
cr
previous
describ
hsu
colleagu
examin
bacteriolog
outpati
cr
compar
antimicrobi
sensit
bacteria
standard
cultur
data
march
august
new
outpati
present
cr
total
patient
endoscopydirect
aerob
cultur
sinu
caviti
cultur
posit
cultur
yield
isol
commonli
isol
organ
scn
p
aeruginosa
aureu
scn
p
aeruginosa
pneumococcu
show
enhanc
antibiot
resist
compar
nonurinari
isol
also
patient
p
aeruginosa
resist
quinolon
data
suggest
patient
cr
enhanc
suscept
antimicrobi
resist
clinic
set
broadspectrum
empir
antibiot
frequent
use
use
broadspectrum
antibiot
regardless
type
specif
pathogen
agent
caus
increas
bacteri
resist
virul
penicillin
group
sensibl
firstlin
antibiot
treatment
sinus
mani
geograph
area
firstlin
agent
fail
high
preval
resist
second
thirdgener
cephalosporin
well
quinolon
suppli
broader
coverag
nevertheless
wide
distribut
bacteri
resist
agent
limit
inappropri
use
antibiot
strongli
consid
bhattacharyya
kepn
carri
crosssect
evalu
prospect
databas
hope
determin
present
incid
transient
pattern
antimicrobi
resist
cr
adult
cr
microbiolog
databas
retrospect
analyz
remov
endoscop
obtain
paranas
sinu
cultur
studi
bacteri
cultur
among
isol
aureu
common
organ
isol
antibiot
resist
increas
dramat
erythromycin
studi
p
remain
unchang
trend
downward
antibiot
use
p
p
p
p
nineteen
percent
aureu
bacteria
found
mrsa
howev
mrsaspecif
antibiot
resist
rate
chang
studi
p
mrsa
bacteria
show
statist
signific
increas
rate
resist
antibiot
test
compar
nonmrsa
collect
conclud
antibiot
resist
develop
erythromycin
higher
rate
antibiot
mrsa
preserv
substanti
occurr
cr
associ
level
increas
antibiot
resist
correctli
obtain
bacteri
isol
local
antibiot
resist
pattern
guid
decis
antimicrobi
treatment
common
recoveri
anaerob
often
posit
mrsa
chronic
maxillari
sinus
recommend
use
antimicrobi
agent
effect
treatment
organ
last
year
sinus
becom
challeng
choos
precis
antimicrobi
agent
becom
complex
like
predomin
bacteri
pathogen
grown
resist
commonli
use
antibiot
three
major
mechan
resist
penicillin
blockag
porin
channel
betalactamas
product
alter
penicillinbind
protein
site
betalactamas
produc
bacteria
blpb
sinus
onethird
ar
cr
blpb
isol
infect
blpb
protect
penicillin
vitro
vivo
shield
betalactamas
activ
shown
ar
cr
antimicrobi
therapi
administr
erad
blpb
oral
antimicrobi
agent
aerob
blpb
ar
oral
agent
blpb
cr
combin
amoxicillin
clavulan
acid
clindamycin
metronidazol
effect
anaerob
pneumonia
penicillin
resist
variat
penicillinbind
protein
nation
rate
resist
isol
date
penicillinresist
strain
highli
resist
penicillinresist
strain
gener
resist
antibiot
bacteri
resist
antibiot
increas
steadili
year
sever
factor
account
increas
resist
includ
prophylaxi
daycar
season
hospit
infect
communic
resist
andor
famili
histori
smoke
